Research ReportSpecific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity
Introduction
Cultures of dissociated primary neurons and astrocytes are frequently used by neurobiologists to study neuronal physiology and pathophysiology. A variety of methods have been used for gene delivery into cultured neurons, including recombinant Sindbis, SV40 or Semliki-forest viral vectors as well as plasmid transfection using calcium phosphate, commercially available lipids or electroporation. However, each of these methods is limited by one or more of the following drawbacks: very low efficiency, short-term gene expression, toxicity, inability to express common reporter genes and/or the requirement to transfect immature neurons (reviewed in Craig, 1998). Although transient, low-efficiency gene expression is sufficient for some types of experiments, biochemical experiments require much higher efficiency.
Adeno-associated viral (AAV) vectors readily transduce neurons in vivo with low toxicity. Here, we report in vitro transduction and toxicity patterns for AAV vectors with 7 different serotypes and 4 AAV vectors with engineered capsids. Several of these vectors mediated efficient, stable and nontoxic transduction of hippocampal and cortical neurons in vitro.
Section snippets
Tropism and efficiency
Recombinant AAV vectors were generated using a CMV-GFP expression cassette as the genome and packaged using capsid sequences from AAV1, 2, 5, 6, 7, 8 or 9. To compare transduction efficiencies of the different AAV serotypes, a single dose of 2.0 − 2.5 × 1011 genome copies (GC) of each vector was added to cultured rat hippocampal cells on day in vitro (DIV) 7. By DIV21, the cultures exposed to serotypes 1, 2, 7, 8 and 9 showed remarkable levels of transduction, approximately 80–94% of the cells in
Discussion
Current methods for gene transfer into cultured neurons are of limited utility due to low efficiency, high toxicity, short duration of gene expression, or the restriction that gene delivery must be performed in immature cells on the day of plating. Transgenic animals can be a source of genetically modified cultures, but generation of these animals is expensive, labor-intensive and mostly restricted to mice. Our results demonstrate that the use of AAV vectors can overcome all of these problems.
Neuronal cultures
The standard culture technique was described previously (Cummings et al., 1996). Briefly, cortices or hippocampi from E19 Sprague–Dawley rat embryos were trypsinized in Dulbecco's minimum essential medium (DMEM; Whittaker Bioproducts) containing 0.027% trypsin at 4 °C for 20 min. They were triturated in media consisting of DMEM supplemented with 10% bovine calf serum (Hyclone), 10% Ham's F12 with glutamine (Whittaker Bioproducts) and 50 U/ml penicillin–streptomycin (Sigma). Dissociated cells
Acknowledgments
This research was supported by grants from the National Institutes of Health RO1 NS040978 (DJW), P30 DK 47757-09 and P01 HL 59407-03 (JMW) and RO1 NS24260 (MAD), by a pilot grant from the University of Pennsylvania Institute for Medicine and Engineering (DJW) and by startup funds from the University of Pennsylvania Department of Neurosurgery (DJW). We thank the Vector and Quality Control Cores of the University of Pennsylvania for producing the vectors, Dr. Virginia Lee for the MAP2 antibody,
References (35)
- et al.
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain
Neuroscience
(2006) - et al.
Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system
Mol. Ther.
(2004) - et al.
A sensitive and selective assay of neuronal degeneration in cell culture
J. Neurosci. Methods
(2006) - et al.
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9 and Rh10 in the mouse brain
Mol. Ther.
(2006) - et al.
Neurotrophin-4/5 protects hippocampal and cortical neurons against energy deprivation- and excitatory amino acid-induced injury
Brain Res.
(1994) - et al.
Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia
Brain Res. Protocols
(2004) - et al.
Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors
Exp. Neurol.
(1998) - et al.
Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain
Exp. Neurol.
(2002) - et al.
Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units
Virology
(2003) - et al.
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector
Brain Res.
(1996)
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer
J. Biol. Chem.
Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry
J. Virol.
Transfecting cultured neurons
Calcium-dependent paired-pulse facilitation of miniature EPSC frequency accompanies depression of EPSCs at hippocampal synapses in culture
J. Neurosci.
Identification of PDGFR as a receptor for AAV-5 transduction
Nat. Med.
Recombinant adeno-associated virus for muscle directed gene therapy
Nat. Med.
New recombinant serotypes of AAV vectors
Curr. Gene Ther.
Cited by (67)
DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease
2023, Progress in NeurobiologyThe use of viral vectors to promote repair after spinal cord injury
2022, Experimental NeurologyA versatile viral toolkit for functional discovery in the nervous system
2022, Cell Reports MethodsCitation Excerpt :As such, we recommend that users validate the specificity and functionality of the VTK vectors using the specific parameters imposed by their experimental design. These various parameters have been extensively tested, and the corresponding studies constitute a valuable resource to guide the experimental design (Dimidschstein et al., 2016; Haery et al., 2019; Royo et al., 2008). Moreover, an essential consideration is the quality of the AAV production; non-specific expression commonly results from the production of AAV particles containing transgenes where recombination occurred during production (Dimidschstein et al., 2016; Haery et al., 2019; Royo et al., 2008).
Gene therapy approaches in central nervous system regenerative medicine
2020, Handbook of Innovations in Central Nervous System Regenerative MedicineGrowth and excitability at synapsin II deficient hippocampal neurons
2019, Molecular and Cellular NeuroscienceCitation Excerpt :The GFP-tagged Syn2 (variant IIa) vector was commercially obtained from Origene (CAT#: MG225317). Neuronal cultures from cells lacking Synapsin II (SynII(−)) at 2 days in vitro (DIV) were exposed to the vector AAV1.hSyn.SYN2-Turbo-GFP.hGh at a moderate dose of 2.5 × 1010 gene copies (GC) per milliliter (Royo et al., 2008), diluted in D-PBS at 37 °C, for ~24 h. After one day, the media containing AAV was exchanged for fresh media.